4 hours ago
1
NSA Digital Archive/iStock via Getty Images
Sarepta Therapeutics (NASDAQ:SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, intensifying scrutiny over the safety of its treatments, Bloomberg reported.
The latest death occurred last month during an early-stage trial
English (US) ·